Introduction
The glycoprotein erythropoietin (EPO) is the central regulator of red blood cell mass, and EPO is regulated primarily at the transcriptional level (1, 2) . The key transcription factor controlling the EPO gene is Hypoxia Inducible Factor, which is composed of an oxygen-sensitive ! subunit (HIF-!) and an oxygen-insensitive " subunit (3) . There are three ! subunit isoforms, HIF-1!, HIF-2!, and HIF-3!. Under normoxic conditions a family of three enzymes known as Prolyl Hydroxylase Domain proteins (PHDs; also known as HIF Prolyl Hydroxylases and Egg Laying Defective Nine proteins) site-specifically hydroxylates HIF-! on two prolyl residues (4) . This modification provides a recognition motif for the von Hippel Lindau tumor suppressor protein (VHL), a component of an E3 ubiquitin ligase complex that targets HIF-! for degradation by the ubiquitin-proteasome pathway (5) . This mechanism allows HIF-! levels to be highly responsive to changes in oxygen concentration, since the hydroxylation reaction utilizes molecular oxygen as a substrate and is also inhibited by reactive oxygen species generated under hypoxic conditions. Thus, under hypoxia, HIF-! is hypohydroxylated and stabilized, allowing it to heterodimerize with HIF-" and transactivate a broad range of genes involved in cellular and systemic responses to hypoxia, of which the EPO gene is a cardinal example (3, 6) .
Idiopathic erythrocytosis is an uncommon disorder characterized by abnormally elevated red cell mass (7, 8) . Investigations have revealed that some cases previously diagnosed as idiopathic erythrocytosis can now be attributed to mutations in proteins of the oxygen-sensing pathway that regulates HIF (9, 10 (12) . Recent studies have shown that mutations in the HIF2A gene (OMIM 611783) comprise a third cause of erythrocytosis attributable to defects in the oxygensensing pathway, and these studies implicate HIF-2! as the central HIF-! isoform regulating EPO in human adults (13) . All reported mutations to date are heterozygous missense mutations that affect residues that are C-terminal to the primary hydroxylation site in HIF-2!, Pro531, and that variably affect the interaction with PHD2 and/or VHL (13) (14) (15) (16) (17) . Collectively, these mutations, while affecting different proteins in the oxygensensing pathway, all lead to aberrant upregulation of HIF-2!.
In this report, we describe a patient with a novel HIF2A mutation associated with erythrocytosis that is predicted to result in a p.Asp539Glu amino acid change. Similar to the mutations previously described, it is a heterozygous mutation affecting a residue Cterminal to the hydroxylacceptor Pro531. Notably, though, this is perhaps the most subtle mutation thus far described, switching one acidic residue with another. As a point of reference, the first HIF-2! mutation described (p.Gly537Trp) changes the smallest amino acid for the bulkiest (13) . Nonetheless, the present mutation impairs interaction of HIF-2! with both PHD2 and VHL, thereby underscoring the exquisite sensitivity of the pathway to what otherwise might be considered a seemingly conservative substitution. 
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Design and Methods
Patient and genetic studies.
The patient is a 17-year old girl of North African ancestry. She has a history of an atrial septal defect, type II, that was closed 15 years ago. At that time, it already came to attention that her hemoglobin level was elevated. Currently, hemoglobin levels are consistently around 17.7 g/dL with red blood cell counts of 6. Both her height as well as weight are -3 SD. She has mild mental retardation.
She has several complaints, that can partly be attributed to her high level of hemoglobin:
headaches, dizziness, dyspnoe d'effort, tiredness and a mild Raynaud phenomenon.
Pulmonary, cardiac, and renal investigations showed no abnormalities. In particular, the patient does not suffer from chronic obstructive pulmonary disease, right-to-left cardiac shunts, or EPO-producing tumors.
Since the patient suffered from dizziness and headaches the efficacy of lowering her hemoglobin to ameliorate her subjective well-being was addressed by repeated phlebotomy. This proved quite successful and could be tapered over time with maintenance of lower hemoglobin levels (in the range of 14.5 -16.1 g/dL).
The inappropriately high level of EPO together with the absence of any pulmonary, cardial, or renal abnormalities suggested a hereditary cause of secondary erythrocytosis in this patient (18, 19) . Therefore, the coding region of genes encoding hemoglobin (HBA In vitro assays.
pcDNA3-GAL4-HIF-2! (516-549) has been described previously (13) . Results shown are representative of two independent experiments.
Results and Discussion
DNA sequence analysis of HBA, HBB, BPGM, PHD2, and VHL showed no abnormalities. However, in HIF2A, a novel heterozygous C>G substitution was identified at nt c.1617, predicting the substitution of aspartic acid at residue 539 by glutamic acid (Figure 1 ). This single base change was not detected among 106 normal control alleles when screened by BbsI digestion.
We assessed the functional consequences of this mutation as follows. First, we The present findings are notable on a number of fronts. First, they support the notion that HIF-2! is the critical isoform regulating EPO in human adults. Second, they indicate that a seemingly conservative substitution is sufficient to disrupt this pathway.
Glutamic acid differs from aspartic acid by only a single methylene group, yet this substitution results in impaired interaction with both PHD2 and VHL. Impairment of both interactions is consistent with the observation of direct contacts between the corresponding residue in HIF-1!, Asp571, and PHD2 and VHL in the crystal structures of the respective complexes (21) (22) (23) . In fact, the interaction of HIF-1! Asp571 with PHD2 and VHL is quite similar, involving salt bridge formation and hydrogen bonding with an arginine residue: Arg396 of PHD2 ( Figure 3A) , and Arg107 of VHL ( Figure 3B ).
The longer side chain of glutamic acid, as compared to aspartic acid, is likely to disrupt these interactions when incorporated at position 571 of HIF-1! (Figure 3) . 
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The corresponding structure of VHL bound to HIF-2!, or of PHD2 bound to HIF-2!, has yet to be reported. Nonetheless, the impaired interaction both with PHD2 and with VHL that is observed with the p.Asp539Glu mutation is also seen with most HIF-2! mutations studied to date (13, 16 ). An exception is the p.Met535Val mutation, which selectively impairs interaction with PHD2 but not with VHL (16). 
